Found: 12
Select item for more details and to access through your institution.
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.
- Published in:
- Molecular Diagnosis & Therapy, 2018, v. 22, n. 6, p. 723, doi. 10.1007/s40291-018-0359-3
- By:
- Publication type:
- Article
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 4, p. 351, doi. 10.1016/j.cllc.2020.12.008
- By:
- Publication type:
- Article
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
- Published in:
- Mediators of Inflammation, 2019, p. 1, doi. 10.1155/2019/7652014
- By:
- Publication type:
- Article
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study.
- Published in:
- Thoracic Cancer, 2021, v. 12, n. 6, p. 880, doi. 10.1111/1759-7714.13852
- By:
- Publication type:
- Article
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 6, p. 1583, doi. 10.1007/s00262-020-02788-1
- By:
- Publication type:
- Article
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 11, p. 2209, doi. 10.1007/s00262-020-02613-9
- By:
- Publication type:
- Article
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
- Published in:
- Cancers, 2020, v. 12, n. 5, p. 1196, doi. 10.3390/cancers12051196
- By:
- Publication type:
- Article
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
- Published in:
- Pathology & Oncology Research, 2019, v. 25, n. 2, p. 513, doi. 10.1007/s12253-018-0404-x
- By:
- Publication type:
- Article